Core Insights - Orexo AB is hosting an R&D Day on March 24, 2026, to present its updated strategy and R&D priorities following the divestment of Zubsolv® in the US [1] - The event will highlight the company's proprietary drug delivery technology, AmorphOX®, which is central to its future development focus [1] Agenda Highlights - The event will feature presentations from CEO Nikolaj Sørensen on strategic priorities and value creation [1] - Discussions will include the transformation of drug delivery methods using AmorphOX® and its applications in various therapeutic areas [1] - The agenda includes expert insights on emerging threats from substances like xylazine and fentanyl, emphasizing the need for medical countermeasures [1] Product Development Focus - Orexo is developing OX640, a nasal epinephrine product aimed at improving stability and patient convenience for severe allergy treatment [1] - OX390 is being developed as a medical countermeasure for overdoses related to xylazine and medetomidine, in collaboration with BARDA [1] - Both OX640 and OX390 are still in the development phase and have not yet received regulatory approval [1] Company Overview - Orexo is a Swedish pharmaceutical company focused on advancing treatments for severe diseases and life-saving medications [1] - The company utilizes AmorphOX® technology to enhance bioavailability and stability for various drug formulations [1] - Orexo has over 30 years of experience and a diversified pipeline in clinical and preclinical development [1]